Who are Solifenacin with vaginal estrogen cream's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/solifenacin-with-vaginal-estrogen-cream.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

Solifenacin with vaginal estrogen cream — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Solifenacin with vaginal estrogen cream (Solifenacin with vaginal estrogen cream) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream). Area: Urology / Gynecology.

marketed Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream) M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen) Urology / Gynecology Small molecule Live · refreshed every 30 min

Target snapshot

Solifenacin with vaginal estrogen cream (Solifenacin with vaginal estrogen cream) — Mackay Memorial Hospital. Solifenacin blocks muscarinic receptors to reduce overactive bladder contractions, while vaginal estrogen cream restores local estrogen levels to improve vaginal atrophy and urogenital symptoms.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Solifenacin with vaginal estrogen cream TARGET	Solifenacin with vaginal estrogen cream	Mackay Memorial Hospital	marketed	Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream)	M3 muscarinic receptor (solifenacin); estrogen receptor (vaginal estrogen)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Anticholinergic agent (solifenacin) + topical estrogen (vaginal cream) class)

Mackay Memorial Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Solifenacin with vaginal estrogen cream — Competitive Intelligence Brief. https://druglandscape.com/ci/solifenacin-with-vaginal-estrogen-cream. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab